Vasopressin in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials

Carregando...
Imagem de Miniatura
Citações na Scopus
33
Tipo de produção
article
Data de publicação
2018
Editora
W B SAUNDERS CO-ELSEVIER INC
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
DUENSER, Martin W.
BOUVET, Olivier
KNOTZER, Hans
ARULKUMARAN, Nish
ULMER, Hanno
HASIBEDER, Walter R.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, v.32, n.5, p.2225-2232, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To summarize the results of randomized controlled trials on the use of vasopressin as a vasopressor agent in cardiac surgery. Design: Meta-analysis. Participants: Six-hundred-twenty-five adult patients undergoing elective or emergency cardiac surgery. Interventions: Arginine vasopressin infusion (n = 313) or control/standard therapy (n = 312). Measurements and Main Results: The rates of perioperative complications and postoperative mortality were used as primary and secondary endpoints, respectively. Fixed and/or random effects models were used to compare pooled odds ratios. Arginine vasopressin reduced the pooled odds ratio (OR) of perioperative complications (OR, 0.33; 95% confidence interval [CI], 0.2-0.54; p < 0.0001). A sensitivity analysis excluding the largest trial showed an unchanged reduction in perioperative complications (OR, 0.35; 95% CI, 0.18-0.69; p = 0.002). When analyzing each perioperative complication separately, vasopressin reduced the pooled OR of vasodilatory shock (OR, 0.4; 95% CI, 0.16-0.97; p = 0.04) and new-onset atrial fibrillation (OR, 0.42; 95% CI, 0.21-0.82; p = 0.01). The pooled OR of postoperative death was not different between patients treated with arginine vasopressin and those receiving standard therapy or placebo (OR, 0.83; 95% CI, 0.45-1.53; p = 0.55). The funnel plot for the primary endpoint suggested a relevant publication bias. All included trials suffered from a high risk of bias. Conclusion: Our meta-analysis suggests that arginine vasopressin may reduce the rate of perioperative complications in patients undergoing elective or emergency cardiac surgery. No difference in postoperative mortality was observed. An adequately powered multicenter trial is required for reliable estimation of the effects of arginine vasopressin on perioperative complication rates and mortality in cardiac surgical patients.
Palavras-chave
Arginine vasopressin, cardiac surgery, mortality, perioperative complications, acute kidney injury, atrial fibrillation, vasodilatory shock
Referências
  1. Argenziano M, J THORAC CARDIOVASC, V116, P973
  2. Belletti A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142605
  3. Dunser MW, 2003, CIRCULATION, V107, P2313, DOI 10.1161/01.CIR.0000066692.71008.BB
  4. Dunser MW, 2002, INTENS CARE MED, V28, P746, DOI 10.1007/s00134-002-1265-y
  5. Dunser MW, 2001, ANESTH ANALG, V93, P7
  6. Elgebaly AS, 2012, ANN CARD ANAESTH, V15, P128, DOI 10.4103/0971-9784.95076
  7. Fischer GW, 2010, SEMIN THORAC CARDIOV, V22, P140, DOI 10.1053/j.semtcvs.2010.09.007
  8. Friesenecker BE, 2006, CRIT CARE, V10, DOI 10.1186/cc4922
  9. Hajjar LA, 2017, ANESTHESIOLOGY, V126, P85, DOI 10.1097/ALN.0000000000001434
  10. Hasija S, 2010, J CARDIOTHOR VASC AN, V24, P230, DOI 10.1053/j.jvca.2009.08.001
  11. Jahangirifard A, 2017, J CELL MOL ANESTH, V2, P97
  12. Mayr A, 2001, ACTA ANAESTH SCAND, V45, P543, DOI 10.1034/j.1399-6576.2001.045005543.x
  13. Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
  14. Morales DLS, 2003, ANN THORAC SURG, V75, P926, DOI 10.1016/S0003-4975(02)04408-9
  15. Morales DLS, 2000, ANN THORAC SURG, V69, P102, DOI 10.1016/S0003-4975(99)01197-2
  16. Okamoto Y, 2015, J CARDIOTHOR VASC AN, V29, P46, DOI 10.1053/j.jvca.2014.07.007
  17. Papadopoulos G, 2010, J CARDIOTHORAC SURG, V5, DOI 10.1186/1749-8090-5-17
  18. Polito A, 2012, INTENS CARE MED, V38, P9, DOI 10.1007/s00134-011-2407-x
  19. QADRI F, 1993, J PHARMACOL EXP THER, V267, P567
  20. Schmittinger CA, 2012, INTENS CARE MED, V38, P950, DOI 10.1007/s00134-012-2531-2
  21. Neto AS, 2012, CRIT CARE, V16, DOI 10.1186/cc11469
  22. Weis F, 2006, ANAESTHESIA, V61, P938, DOI 10.1111/j.1365-2044.2006.04779.x